Patents by Inventor Xianming Jin

Xianming Jin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds And Compositions As Protein Kinase Inhibitors
    Publication number: 20230116233
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
    Type: Application
    Filed: April 20, 2022
    Publication date: April 13, 2023
    Inventors: Shenlin Huang, Xianming Jin, Zuosheng Liu, Daniel Poon, John Tellew, Yongqin Wan, Xing Wang, Yongping Xie
  • GLUE DEGRADERS AND METHODS OF USE THEREOF
    Publication number: 20220363671
    Abstract: Described herein are glue degrader compounds, their various targets, their preparation, pharmaceutical compositions comprising them, and their use in the treatment or prevention of conditions, diseases, and disorders mediated by various target proteins.
    Type: Application
    Filed: September 16, 2020
    Publication date: November 17, 2022
    Inventors: Jake AXFORD, Rohan Eric John BECKWITH, Simone BONAZZI, Nicole BUSCHMANN, Artiom CERNIJENKO, Janetta DEWHURST, Aleem FAZAL, Matthew James HESSE, Lauren HOLDER, Viktor HORNAK, Hidetomo IMASE, Rama JAIN, Xianming JIN, John Ryan KERRIGAN, Julie LACHAL, Fupeng MA, Hasnain Ahmed MALIK, James R. MANNING, Daniel MCKAY, Robert Joseph MOREAU, Pierre NIMSGERN, Gary O'BRIEN, Anna VULPETTI, Ken YAMADA, Junping ZHAO
  • FUSED TRICYCLIC PYRAZOLO-DIHYDROPYRAZINYL-PYRIDONE COMPOUNDS AS ANTIVIRALS
    Publication number: 20220105091
    Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions and pharmaceutical combinations containing such compounds, as well as methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus (HBV), and for reducing the occurrence of serious conditions associated with HBV.
    Type: Application
    Filed: December 14, 2021
    Publication date: April 7, 2022
    Inventors: Jiping Fu, Wooseok Han, Xianming Jin, Keith Bruce Pfister, Joseph Michael Young
  • Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals
    Patent number: 11234977
    Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions and pharmaceutical combinations containing such compounds, as well as methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus (HBV), and for reducing the occurrence of serious conditions associated with HBV.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: February 1, 2022
    Assignee: Novartis AG
    Inventors: Jiping Fu, Wooseok Han, Xianming Jin, Keith Bruce Pfister, Joseph Michael Young
  • Fused Tricyclic Pyrazolo-Dihydropyrazinyl-Pyridone Compounds as Antivirals
    Publication number: 20210346377
    Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions and pharmaceutical combinations containing such compounds, as well as methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus (HBV), and for reducing the occurrence of serious conditions associated with HBV.
    Type: Application
    Filed: December 19, 2018
    Publication date: November 11, 2021
    Inventors: Jiping FU, Wooseok HAN, Xianming JIN, Keith Bruce PFISTER, Joseph Michael YOUNG
  • INDOLE-2-CARBONYL COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HEPATITIS B
    Publication number: 20200407365
    Abstract: The invention provides compounds of Formula (I), as described herein, along with stereoisomeric forms salts, hydrates, solvates, and salts thereof and pharmaceutical compositions and pharmaceutical combinations containing such compounds, as well as methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus (HBV), and for reducing the occurrence of serious conditions associated with HBV.
    Type: Application
    Filed: February 26, 2019
    Publication date: December 31, 2020
    Inventors: Jiping FU, Rama JAIN, Xianming JIN, Xiaodong LIN, Mika LINDVALL, James R. MANNING, Glenn MCENROE
  • Compounds And Compositions As Protein Kinase Inhibitors
    Publication number: 20200323852
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
    Type: Application
    Filed: January 14, 2020
    Publication date: October 15, 2020
    Inventors: Shenlin Huang, Xianming Jin, Zuosheng Liu, Daniel Poon, John Tellew, Yongqin Wan, Xing Wang, Yongping Xie
  • TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS
    Publication number: 20200270265
    Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.
    Type: Application
    Filed: February 16, 2017
    Publication date: August 27, 2020
    Inventors: Jiping FU, Xianming JIN, Patrick LEE, Peichao LU, Joseph Michael YOUNG
  • Aminoheteroaryl benzamides as kinase inhibitors
    Patent number: 10660888
    Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: May 26, 2020
    Assignee: NOVARTIS AG
    Inventors: Jeffrey T. Bagdanoff, Yu Ding, Wooseok Han, Zilin Huang, Qun Jiang, Xianming Jin, Xiang Kou, Patrick Lee, Mika Lindvall, Zhongcheng Min, Yue Pan, Sabina Pecchi, Keith Bruce Pfister, Daniel Poon, Vivek Rauniyar, Xiaojing Michael Wang, Qiong Zhang, Jianguang Zhou, Shejin Zhu
  • Compounds and compositions as protein kinase inhibitors
    Patent number: 10576080
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: March 3, 2020
    Assignee: Array BioPharma Inc.
    Inventors: Shenlin Huang, Xianming Jin, Zuosheng Liu, Daniel Poon, John Tellew, Yongqin Wan, Xing Wang, Yongping Xie
  • Compounds and compositions as protein kinase inhibitors
    Patent number: 10568884
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: February 25, 2020
    Assignee: Array BioPharma Inc.
    Inventors: Shenlin Huang, Xianming Jin, Zuosheng Liu, Daniel Poon, John Tellew, Yongqin Wan, Xing Wang, Yongping Xie
  • AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS
    Publication number: 20190247392
    Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.
    Type: Application
    Filed: December 5, 2018
    Publication date: August 15, 2019
    Inventors: Jeffrey T. BAGDANOFF, Yu DING, Wooseok HAN, Zilin HUANG, Qun JIANG, Xianming JIN, Xiang KOU, Patrick LEE, Mika LINDVALL, Zhongcheng MIN, Yue PAN, Sabina PECCHI, Keith Bruce PFISTER, Daniel POON, Vivek RAUNIYAR, Xiaojing Michael WANG, Qiong ZHANG, Jianguang ZHOU, Shejin ZHU
  • Aminoheteroaryl benzamides as kinase inhibitors
    Patent number: 10188649
    Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: January 29, 2019
    Assignee: Novartis AG
    Inventors: Jeffrey T. Bagdanoff, Yu Ding, Wooseok Han, Zilin Huang, Qun Jiang, Xianming Jin, Xiang Kou, Patrick Lee, Mika Lindvall, Zhongcheng Min, Yue Pan, Sabina Pecchi, Keith Bruce Pfister, Daniel Poon, Vivek Rauniyar, Xiaojing Michael Wang, Qiong Zhang, Jianguang Zhou, Shejin Zhu
  • COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
    Publication number: 20180297985
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
    Type: Application
    Filed: November 20, 2017
    Publication date: October 18, 2018
    Inventors: Shenlin Huang, Xianming Jin, Zuosheng Liu, Daniel Poon, John Tellew, Yongqin Wan, Xing Wang, Yongping Xie
  • COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
    Publication number: 20180297986
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
    Type: Application
    Filed: November 20, 2017
    Publication date: October 18, 2018
    Inventors: Shenlin Huang, Xianming Jin, Zuosheng Liu, Daniel Poon, John Tellew, Yongqin Wan, Xing Wang, Yongping Xie
  • Tetracyclic pyridone compounds as antivirals
    Patent number: 10093673
    Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: October 9, 2018
    Assignee: Novartis AG
    Inventors: Jiping Fu, Xianming Jin, Patrick Lee, Peichao Lu, Joseph Michael Young
  • Isoxazole hydroxamic acid compounds as LpxC inhibitors
    Patent number: 10029994
    Abstract: This invention pertains generally to compounds of Formula I as described herein and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention provides methods and compositions comprising these compounds for treating infections caused by Gram-negative bacteria.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: July 24, 2018
    Assignee: Novartis AG
    Inventors: Jiping Fu, Xianming Jin, Subramanian Karur, Guillaume Lapointe, Ann Marie Madera, Zachary Kevin Sweeney
  • Compounds and compositions as protein kinase inhibitors
    Patent number: 10005761
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: June 26, 2018
    Assignee: Array BioPharma Inc.
    Inventors: Shenlin Huang, Xianming Jin, Zuosheng Liu, Daniel Poon, John Tellew, Yongqin Wan, Xing Wang, Yongping Xie
  • AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS
    Publication number: 20180028532
    Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.
    Type: Application
    Filed: August 9, 2017
    Publication date: February 1, 2018
    Applicant: Novartis AG
    Inventors: Jeffrey T. BAGDANOFF, Yu DING, Wooseok HAN, Zilin HUANG, Qun JIANG, Xianming JIN, Xiang KOU, Patrick LEE, Mika LINDVALL, Zhongcheng MIN, Yue PAN, Sabina PECCHI, Keith Bruce PFISTER, Daniel POON, Vivek RAUNIYAR, Xiaojing Michael WANG, Qiong ZHANG, Jianguang ZHOU, Shejin ZHU
  • Compounds and compositions as protein kinase inhibitors
    Patent number: RE49556
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: June 20, 2023
    Assignee: ARRAY BIOPHARMA INC.
    Inventors: Shenlin Huang, Xianming Jin, Zuosheng Liu, Daniel Poon, John Tellew, Yongqin Wan, Xing Wang, Yongping Xie